Stem cell treatment for advanced age-related macular degeneration
Part of Eyes & vision clinical trials.
This study tests a new treatment that uses your own stem cells to create retinal cells, which are then placed in your eye. The goal is to see if this can help improve vision for people with advanced age-related macular degeneration.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 55 and 80 years old.
- You need to have advanced age-related macular degeneration (AMD), which is a common eye condition that causes vision loss.
- Your vision in the study eye should be very poor — worse than 20/200 (meaning you can barely see the big letter on an eye chart).
- You must not have a history of cancer, immune deficiency, or severe heart, kidney, or liver disease.
- You should not have had eye surgery other than cataract surgery.
- You need to be willing to follow the study schedule and sign consent forms.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests a new cell-based treatment (C.001) for inherited retinal diseases that affect the back of the eye. The treatment may help slow vision loss or improve sight in people with geographic atrophy or Stargardt disease.
This study looks at stem-cell treatment to help vision in adults whose retina or optic nerve damage is not expected to improve on its own. You may be a candidate if your eye exam shows documented, stable or slowly changing damage and you can safely complete follow-up eye visits.
This trial tests a new treatment called Eyecyte-RPE™, made from special cells that support the retina. It is given as a single injection under the retina during eye surgery. The study aims to see if it can help people with advanced dry age-related macular degeneration (AMD) who have large areas of damage (geographic atrophy) in the center of their vision.
This study collects immune cells (from a blood sample) from people with certain types of age-related macular degeneration (AMD) and compares how long they live. It may help researchers understand how immune-related changes relate to AMD outcomes.
This trial tests a gene therapy (KH658) as a one-time treatment for wet macular degeneration. It's for people whose condition has been stabilized with anti-VEGF injections, and aims to see if it is safe and can reduce the need for frequent eye injections.
This trial tests a new stem-cell treatment for people with advanced dry age-related macular degeneration (AMD), a condition that causes blurring or loss of central vision. It aims to replace damaged cells in the back of the eye to potentially slow vision loss and improve day-to-day sight.
Hear when a new Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.